Johnson and Johnson News Archives

A new study raises fresh safety concerns about widely used anemia medicines, finding that the drug Aranesp nearly doubled the risk of stroke in people with diabetes and chronic kidney problems who are not yet sick enough to need dialysis.

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.

Main Category: Cosmetic Medicine / Plastic Surgery Article Date: 28 Oct 2009 - 2:00 PDT An injured Iraqi citizen, a port wine stain patient, a breast reconstruction patient and a skin cancer patient will be named honorees of the Patients of Courage: Triumph Over Adversity awards by the American Society of Plastic Surgeons at Plastic Surgery 2009, ...

Today the Tenth Circuit handed down a very interesting Fourth Amendment decision, United States v. Johnson , on whether an individual can have a reasonable expectation of privacy in a storage unit rented with a stolen identity.

To appreciate the impact of crisis project management, it's important to understand how the discipline started.

Based on the aggregated intelligence of 140,000-plus investors participating in Motley Fool CAPS , the Fool's free investing community, Swiss pharmaceuticals giant Novartis has earned a coveted five-star ranking .

Johnson & Johnson executives said Tuesday a proposed tax on medical device makers, part of the health care reform package moving in the Senate, is too high and could cost jobs in the industry.

The strong bullish move off of March 2009 lows has lifted many stocks, thus creating large unrealized paper gains for many dividend investors.

That pesky human papillomavirus got a double dose of bad news on Friday, as vaccines against the virus from Merck and GlaxoSmithKline were approved by the Food and Drug Administration for different indications.

Just when it looked like Amgen was turning things around a whack! The Food and Drug Administration has thrown a wrench in the biotech's plans.

Filed under: Earnings reports , Johnson and Johnson , Procter and Gamble , Kimberly-Clark Kimberly-Clark Corporation , a consumer products entity whose colleagues include Procter & Gamble and Johnson & Johnson , is up today on third-quarter results.

Based on the aggregated intelligence of 140,000-plus investors participating in Motley Fool CAPS , the Fool's free investing community, generic-drug specialist Teva Pharmaceutical has earned a coveted five-star ranking .

Schering-Plough Corp. reported lower third-quarter earnings early Thursday, due primarily to charges taken for its 2007 acquisition of Organon BioSciences NV and its impending merger with Merck & Co.

Campbell Soup Company earned a Reputation Pulse score of 83.33 on a scale of 1 to 100 to place second behind Johnson & Johnson, according to the Reputation Institute and the Boston College Center for Corporate Citizenship, in a survey of Americans to determine which companies have earned the strongest levels of trust, admiration, respect and good ...

Pharmaceutical company Elan has reported a net profit of $52.3m for the third quarter of this year, a turnaround from the $83.5m loss in the same period last year.

Boston Scientific Corp. said Monday that it swung to a third-quarter profit, due in part to a slew of charges taken by the company in the same period last year.

It's time for Apple to put up or shut up. Apple reports earnings after market close tonight, and the gadget guru has everything to prove .

Mylan Inc. will pay $121 million to settle claims it did not properly reimburse Medicaid for drugs, while two other drugmakers are making smaller payments.

Boston Scientific Corp on Monday reported a quarterly net profit, compared with a year-ago loss, but cut its full-year earnings outlook, citing weakness in the market for implantable heart defibrillators.

Everyone loves a chance to avoid paying huge amounts of taxes, and for many people, opening a Roth IRA could give you exactly that opportunity.

The Toronto stock market continues to demonstrate resilience as a key week of U.S. earnings encouraged investors that an economic recovery is in the works.

Johnson & Johnson knows how to make nurses feel special. But this time, they outdid themselves.

One of the largest gatherings of medical bloggers took place this past week at Blog World Expo 2009 in Las Vegas.

European and U.S. stock markets fell from 2009 highs Tuesday after consumer healthcare company Johnson & Johnson disappointed investors with declining third-quarter sales and financial companies were sold off after an analyst downgrade of Goldman Sachs Group Inc.

Filed under: Google , General Electric , Johnson and Johnson , Advanced Micro Dev , Bank of America Today's earnings were deemed a disappointment despite some bottom-line comfort here.

Stocks rallied Wednesday afternoon, with the Dow industrials briefly touching 10,000 for the first time in over a year, following better-than-expected quarterly profit reports from Intel and JPMorgan Chase.

Maybe Wall Street is getting too accustomed to Baxter International beating consensus earnings estimates.

A surprisingly strong profit and outlook from Intel and much stronger-than-forecast results from J.P. Morgan Chase sent U.S. stock futures rallying and put a 10,000 level on the Dow Jones Industrial Average within reach.

Intel Corp., the world's largest chip maker, will lead off quarterly-earnings reports from technology sector bellwethers on Tuesday evening.

Japanese stocks posted their fifth straight rise Tuesday, lifted by broader Asian gains and bullish expectations for steelmakers.

It's likely to be some time before health-care companies begin to enjoy the fruits of any economic recovery, judging by Johnson & Johnson's slight third-quarter revenue miss on Oct.

As the U.S. stock market on Wednesday basked in better-than-anticipated results from bellwethers Intel Corp.

Simon Davies, the former marketing director of Molson Coors who left the brewer after 13 years at the start of this month, has opened a new strategic and creative agency in Manchester.

The U.S. dollar was weaker in Asia yesterday as investors bought riskier assets on hopes that upcoming U.S. corporate news will support economic recovery sentiment, dealers said.

Wednesday, October 14, 2009 LONDON: Oil rose for the fourth straight session on Tuesday, edging higher above $73 a barrel after OPEC raised its 2010 demand forecast and the dollar slumped.

Roche, which has sealed a $47 billion buyout of U.S. partner Genentech, on Thursday nudged up its full year forecast for the drugs unit, now seeing at least high single-digit sales growth, and confirmed its earnings target.

Stock futures turned mostly lower on Tuesday as Johnson & Johnson's third-quarter sales figures disappointed investors, offsetting a lift from higher commodity prices that rose with the weaker U.S. dollar.

Disappointing quarterly sales from Johnson & Johnson and a warning that bank shares are overheated gave investors reason to trade cautiously.

Abbott Laboratories said Wednesday it beat its own expectations for the third quarter as sales of its drug Humira continued to climb, along with sales of medical products and nutritional formula for children.

Johnson & Johnson , the worlda s largest health products company, said profit rose 1.1 percent as cost-cuts offset declining sales.

The dollar fell to an annual low against the euro Tuesday after a dip in German investor confidence and disappointing earnings results failed to undermine expectations of economic recovery.

Treasurys rose Tuesday, rebounding from a big sell-off last week, as investors awaited more clues on the economy from companies' earnings reports.

The major averages pared early losses, brushing off mixed signals from Johnson & Johnson's earnings and Meredith Whitney's downgrade of Goldman Sachs .

Oct. 13 - Worries of a lackluster rebound in corporate sales resurfaced after weaker-than-expected quarterly revenues at personal health care giant Johnson & Johnson.

Drug stocks were mixed in trading early Tuesday as shares of Johnson & Johnson slid after it issued a lackluster third-quarter earnings report.

In this July 14, 2009 file photo, a box of Johnson & Johnson BAND-AID bandages is shown in Boston .

Most Asian stock markets advanced Tuesday, with Tokyo and Hong Kong indexes gaining almost 1 percent, as investors looked to earnings reports from major U.S. companies for insight about the economy.

Stocks are extending recent gains at the start of a busy week of earnings, nudging the Dow Jones industrial average closer to 10,000. Major market indicators rose moderately Monday, including the Dow, which rose as much as 67 points to hit a new 2009 high of 9,931. That's just 69 points away from 10,000, a level not seen in a year.

At a panel discussion at the Pew Charitable Trusts , Alice Rivlin floated the idea of breaking up big banks.

For a sense of the economy, it is a good week to track the earnings reports from Wall Street.

Oil prices rose above $72 a barrel Monday in Asia as investors looked to a slew of U.S. corporate earnings reports this week for signs of economic recovery.

Johnson & Johnson - in partnership with Gannett Healthcare Group, publishers of Nursing Spectrum, NurseWeek and Nurse.com - delivered on its promise to Maryland nurses by raising more than $500,000 at the Promise of Nursing for Maryland gala Sept.

Johnson & Johnson, the world's biggest healthcare company and a Dow Jones industrial average component, reports earnings for the third quarter Tuesday morning.

Posted by: Pat Powers - 10/08/2009 8:51 AM As I've continued to look at the Johnson & Johnson nepotism saga, I seem to distinctly recall that in Senator Johnson's defense, many of the Democratic commenters sputter in rebuttal "...but, but... Senator Johnson said he would have nothing to do with the process...." And to their credit, yes, that's what ...

Tax authorities filed a criminal complaint against the former director of the Japanese subsidiary of pharmaceutical giant Johnson & Johnson, saying he hid 160 million yen from stock options in overseas accounts, sources said.

Ted Torphy, chief scientific officer at Johnson & Johnson, was the moderator at the MassBio Investors Forum at the Sheraton Boston.

You're probably getting all sorts of conflicting messages these days. On the one hand, just months ago you heard gloom-and-doom predictions from luminary economists like Nouriel "Dr. Doom" Roubini, calling an S&P 500 bottom possibly as low as 600 -- roughly 40% below yesterday's close.

Milestone payments have Vertex Pharmaceuticals Inc. seeing green with an expected cash infusion of $155 million from two separate transactions.

Johnson & Johnson must be loving their new deal with Elan. Remember, this was the deal in which they paid $1.4 billion for a stake in the company, including $500 million for its Alzheimera s drugs, such as bapineuzumab , and still didn't come away with Tysabri , the MS wonder drug.

In the latest sign that Pfizer Inc.'s $68 billion purchase of Wyeth will go through, Wyeth's stock has been removed from two key investor indices.

THE logic in favour of purchases of vaccine firms seems irrefutable. The world is in the grip of a swine-flu pandemic, which will probably infect 40% or more of the human race.